secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-01-27T23:59:59+00:00
Accession:  0001213900-26-008210
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar enters quiet period ahead of Phase 2b REZOLVE-AD maintenance data; data expected in February 2026
--------------------------------------------------------------------------------

- Quiet period begins January 27, 2026 and continues until public announcement of the maintenance data.
- Maintenance Data are from the 36-week maintenance period of the Phase 2b REZOLVE-AD study of rezpegaldesleukin.
- Next investor communication planned for February 2026 at the time of data presentation.
- This quiet period is consistent with prior quiet periods for REZOLVE studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390026008210/0001213900-26-008210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390026008210/ea0274309-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-008210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer